image credit: Adobe Stock

How eligible patient numbers affect price of rare disease drugs in France

December 7, 2022


Pricing and market access in France operate on a dual system, under which health technology assessments (HTAs) are conducted separately from pricing negotiations. The HTA body, the CT (Commission de la Transparence – Transparency Commission), is charged with providing guidance to inform pricing negotiations in two main forms: a comparative clinical benefit rating, the ASMR (Amélioration du Service Médical Rendu), and a target patient population.

Read More on Pharmaphorum